{
    "clinical_study": {
        "@rank": "151305", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sequence 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sequence 4", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to\n      Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on\n      GS-9973 Pharmacokinetics."
        }, 
        "brief_title": "A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have the ability to understand and sign a written informed consent form, which must\n             be obtained prior to initiation of study procedures\n\n          -  Must have a body mass index (BMI) range of approximately 19 to 30 kg/m2\n\n          -  Must have a minimum weight of 45 kg\n\n          -  Females of childbearing potential must have negative serum pregnancy tests at\n             screening and baseline and must practice at least 1 reliable method of contraception\n             as defined by the protocol\n\n               -  Female subjects who utilize hormonal contraceptive as 1 of their birth control\n                  methods must have used the same method for at least 3 months prior to study\n                  dosing\n\n          -  Male subjects must agree to use condoms during heterosexual intercourse and avoid\n             sperm donation from Day -1 until 90 days following the last dose of study medication\n\n          -  Must refrain from blood donation throughout the study period\n\n          -  Must, in the opinion of the Investigator, be in good general\n\n          -  Must be a non- or light smoker, eg, less than 10 cigarettes per day\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating subjects\n\n          -  Use of prescribed or over-the-counter medications that affect gastric pH\n\n          -  History of severe peptic ulcer disease, GERD, or other diseases requiring\n             prolonged(>6 weeks) medication or surgical therapy to modify gastric pH\n\n          -  Have a history of clinically significant cardiac abnormalities or presence of\n             clinically significant abnormality on 12-lead ECG.\n\n          -  Have a history of any cancer requiring systemic chemotherapy or radiation\n\n          -  Have a history of bleeding disorders\n\n          -  Have a history of liver disorders\n\n          -  Current acute infection or history of acute infection within 7 days\n\n          -  Have a recent history of alcohol or illicit drug abuse and/or have a positive test\n             for selected drugs of abuse\n\n          -  Have a positive hepatitis screen or positive Human Immunodeficiency Virus antibody\n             test\n\n          -  Have participated in another clinical trial within 28 days\n\n          -  Have received transfusion of blood or plasma products within 6 months\n\n          -  Have donated > 500 mL blood within 56 days\n\n          -  Are unable or unwilling to comply with study restrictions, return for follow-up\n             appointments, or other considerations, which in the opinion of the Investigator,\n             would make the candidate unsuitable for study participation\n\n          -  Current or historical medical condition that is deemed to be of medical significance\n             by the Investigator\n\n          -  Have used prescription medications, over the counter products, herbal remedies and\n             nutritional supplements within 7 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841489", 
            "org_study_id": "GS-US-339-0111"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2"
                ], 
                "description": "1600 mg GS-9973 (Formulation 1)", 
                "intervention_name": "Treatment A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence 1", 
                "description": "1600 mg GS-9973 (Formulation 1)  plus 20 mg omeprazole", 
                "intervention_name": "Treatment B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "description": "1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine", 
                "intervention_name": "Treatment C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "description": "1600 mg GS-9973 (Formulation 2)", 
                "intervention_name": "Treatment D", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence 3", 
                "description": "1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole", 
                "intervention_name": "Treatment E", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sequence 4", 
                "description": "1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine", 
                "intervention_name": "Treatment F", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 3"
                ], 
                "description": "1600 mg GS-9973 (Reference formulation)", 
                "intervention_name": "Treatment G", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 2", 
                    "Sequence 4"
                ], 
                "description": "1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)", 
                "intervention_name": "Treatment H", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 3"
                ], 
                "description": "An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily", 
                "intervention_name": "Treatment I", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 2", 
                    "Sequence 4"
                ], 
                "description": "An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily", 
                "intervention_name": "Treatment J", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Chronic Lymphocytic Leukemia", 
            "CLL"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Daytona Beach", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32117"
                }, 
                "name": "Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Michael Hawkins, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure is the pharmacokinetic (PK) parameters for GS-9973 including AUC and Cmax.", 
            "measure": "Pharmacokinetic parameters for GS-9973", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841489"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A secondary outcome measure is the pharmacokinetic parameters for GS-9973 including Ctau and AUClast.", 
                "measure": "Secondary pharmacokinetic parameters for GS-9973", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "A secondary outcome measure is the safety and tolerability of GS-9973 which will be evaluated by the incidence of AEs including assessment of clinical laboratory test findings, physical examinations, 12-lead ECG abnormalities, and vital signs measurements.", 
                "measure": "Incidence of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "A secondary outcome measure is the blood pharmacodynamic parameters.", 
                "measure": "Blood PD parameters for GS-9973", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}